Consumer willingness to pay for a hypothetical Chikungunya vaccine in Brazil and the implications

Túlio Tadeu Sarmento, Isabella Piassi Godói, Edna Afonso Reis, Brian Godman, Cristina Mariano Ruas

Research output: Contribution to conferencePoster

Abstract

Background: Chikungunya fever is an important infectious disease transmitted by the bite of Aedes genus mosquitoes infected with the Chikungunya Virus (CHIKV). Information about consumers’ willingness to pay (WTP) for a hypothetical vaccine against CHIKV can help discussions about prices and funding in countries with limited resources. Methods: Cross-sectional study among adult residents of Minas Gerais, Brazil, asking if they were willing to pay the price for a hypothetical chikungunya vaccine defined by the authors with an effective protection of 80% and the possibility of local and systemic side-effects. Residents were provided with information if not familiar with the virus. The price was randomly varied between participants in five values: US$11.69 (45.00BRL), US$23.38 (90.00BRL), US$46.75 (180.00BRL), US$93.51 (360.00BRL) and US$187.90 (720.00BRL). We included this aspect due to issues with any anchoring effect. Results: 496 individuals were interviewed. Among these, 23 were excluded. Most of the respondents were female (57.3%), had completed at least high school (90.7%), were employed (87.7%) and had private health insurance (62.6%). The median value of the WTP was US$ 31.17 (120.00 BRL) for a unique dose vaccine. There was a statistical significant correlation with monthly family income and access to private health insurance. Conclusion: This study can contribute to decision-making about potential prices for a CHIKV vaccine when it becomes available in Brazil. We also showed the anchoring effect as a possible influence on consumers’ WTP in studies with similar techniques. Finally, we encourage the development of a chikungunya virus vaccine to benefit the Brazilian population.
Original languageEnglish
Number of pages1
Publication statusAccepted/In press - 2 Dec 2019
EventEuroDURG 2020 - Szeged, Hungary
Duration: 4 Mar 20207 Mar 2020

Conference

ConferenceEuroDURG 2020
CountryHungary
CitySzeged
Period4/03/207/03/20

Fingerprint

Chikungunya virus
Brazil
Vaccines
Health Insurance
Aedes
Bites and Stings
Culicidae
Communicable Diseases
Decision Making
Cross-Sectional Studies
Viruses
Population

Keywords

  • Chikungunya vaccine
  • willingness to pay
  • Brazil

Cite this

Sarmento, T. T., Godói, I. P., Reis, E. A., Godman, B., & Ruas, C. M. (Accepted/In press). Consumer willingness to pay for a hypothetical Chikungunya vaccine in Brazil and the implications. Poster session presented at EuroDURG 2020, Szeged, Hungary.
Sarmento, Túlio Tadeu ; Godói, Isabella Piassi ; Reis, Edna Afonso ; Godman, Brian ; Ruas, Cristina Mariano . / Consumer willingness to pay for a hypothetical Chikungunya vaccine in Brazil and the implications. Poster session presented at EuroDURG 2020, Szeged, Hungary.1 p.
@conference{1f35f10e70ad427c8e0c2de4e7b1f214,
title = "Consumer willingness to pay for a hypothetical Chikungunya vaccine in Brazil and the implications",
abstract = "Background: Chikungunya fever is an important infectious disease transmitted by the bite of Aedes genus mosquitoes infected with the Chikungunya Virus (CHIKV). Information about consumers’ willingness to pay (WTP) for a hypothetical vaccine against CHIKV can help discussions about prices and funding in countries with limited resources. Methods: Cross-sectional study among adult residents of Minas Gerais, Brazil, asking if they were willing to pay the price for a hypothetical chikungunya vaccine defined by the authors with an effective protection of 80{\%} and the possibility of local and systemic side-effects. Residents were provided with information if not familiar with the virus. The price was randomly varied between participants in five values: US$11.69 (45.00BRL), US$23.38 (90.00BRL), US$46.75 (180.00BRL), US$93.51 (360.00BRL) and US$187.90 (720.00BRL). We included this aspect due to issues with any anchoring effect. Results: 496 individuals were interviewed. Among these, 23 were excluded. Most of the respondents were female (57.3{\%}), had completed at least high school (90.7{\%}), were employed (87.7{\%}) and had private health insurance (62.6{\%}). The median value of the WTP was US$ 31.17 (120.00 BRL) for a unique dose vaccine. There was a statistical significant correlation with monthly family income and access to private health insurance. Conclusion: This study can contribute to decision-making about potential prices for a CHIKV vaccine when it becomes available in Brazil. We also showed the anchoring effect as a possible influence on consumers’ WTP in studies with similar techniques. Finally, we encourage the development of a chikungunya virus vaccine to benefit the Brazilian population.",
keywords = "Chikungunya vaccine, willingness to pay, Brazil",
author = "Sarmento, {T{\'u}lio Tadeu} and God{\'o}i, {Isabella Piassi} and Reis, {Edna Afonso} and Brian Godman and Ruas, {Cristina Mariano}",
year = "2019",
month = "12",
day = "2",
language = "English",
note = "EuroDURG 2020 ; Conference date: 04-03-2020 Through 07-03-2020",

}

Sarmento, TT, Godói, IP, Reis, EA, Godman, B & Ruas, CM 2019, 'Consumer willingness to pay for a hypothetical Chikungunya vaccine in Brazil and the implications' EuroDURG 2020, Szeged, Hungary, 4/03/20 - 7/03/20, .

Consumer willingness to pay for a hypothetical Chikungunya vaccine in Brazil and the implications. / Sarmento, Túlio Tadeu ; Godói, Isabella Piassi; Reis, Edna Afonso; Godman, Brian; Ruas, Cristina Mariano .

2019. Poster session presented at EuroDURG 2020, Szeged, Hungary.

Research output: Contribution to conferencePoster

TY - CONF

T1 - Consumer willingness to pay for a hypothetical Chikungunya vaccine in Brazil and the implications

AU - Sarmento, Túlio Tadeu

AU - Godói, Isabella Piassi

AU - Reis, Edna Afonso

AU - Godman, Brian

AU - Ruas, Cristina Mariano

PY - 2019/12/2

Y1 - 2019/12/2

N2 - Background: Chikungunya fever is an important infectious disease transmitted by the bite of Aedes genus mosquitoes infected with the Chikungunya Virus (CHIKV). Information about consumers’ willingness to pay (WTP) for a hypothetical vaccine against CHIKV can help discussions about prices and funding in countries with limited resources. Methods: Cross-sectional study among adult residents of Minas Gerais, Brazil, asking if they were willing to pay the price for a hypothetical chikungunya vaccine defined by the authors with an effective protection of 80% and the possibility of local and systemic side-effects. Residents were provided with information if not familiar with the virus. The price was randomly varied between participants in five values: US$11.69 (45.00BRL), US$23.38 (90.00BRL), US$46.75 (180.00BRL), US$93.51 (360.00BRL) and US$187.90 (720.00BRL). We included this aspect due to issues with any anchoring effect. Results: 496 individuals were interviewed. Among these, 23 were excluded. Most of the respondents were female (57.3%), had completed at least high school (90.7%), were employed (87.7%) and had private health insurance (62.6%). The median value of the WTP was US$ 31.17 (120.00 BRL) for a unique dose vaccine. There was a statistical significant correlation with monthly family income and access to private health insurance. Conclusion: This study can contribute to decision-making about potential prices for a CHIKV vaccine when it becomes available in Brazil. We also showed the anchoring effect as a possible influence on consumers’ WTP in studies with similar techniques. Finally, we encourage the development of a chikungunya virus vaccine to benefit the Brazilian population.

AB - Background: Chikungunya fever is an important infectious disease transmitted by the bite of Aedes genus mosquitoes infected with the Chikungunya Virus (CHIKV). Information about consumers’ willingness to pay (WTP) for a hypothetical vaccine against CHIKV can help discussions about prices and funding in countries with limited resources. Methods: Cross-sectional study among adult residents of Minas Gerais, Brazil, asking if they were willing to pay the price for a hypothetical chikungunya vaccine defined by the authors with an effective protection of 80% and the possibility of local and systemic side-effects. Residents were provided with information if not familiar with the virus. The price was randomly varied between participants in five values: US$11.69 (45.00BRL), US$23.38 (90.00BRL), US$46.75 (180.00BRL), US$93.51 (360.00BRL) and US$187.90 (720.00BRL). We included this aspect due to issues with any anchoring effect. Results: 496 individuals were interviewed. Among these, 23 were excluded. Most of the respondents were female (57.3%), had completed at least high school (90.7%), were employed (87.7%) and had private health insurance (62.6%). The median value of the WTP was US$ 31.17 (120.00 BRL) for a unique dose vaccine. There was a statistical significant correlation with monthly family income and access to private health insurance. Conclusion: This study can contribute to decision-making about potential prices for a CHIKV vaccine when it becomes available in Brazil. We also showed the anchoring effect as a possible influence on consumers’ WTP in studies with similar techniques. Finally, we encourage the development of a chikungunya virus vaccine to benefit the Brazilian population.

KW - Chikungunya vaccine

KW - willingness to pay

KW - Brazil

UR - https://www.eurodurg2020.com/

M3 - Poster

ER -

Sarmento TT, Godói IP, Reis EA, Godman B, Ruas CM. Consumer willingness to pay for a hypothetical Chikungunya vaccine in Brazil and the implications. 2019. Poster session presented at EuroDURG 2020, Szeged, Hungary.